Shire rejects £27bn takeover AbbVie bid
Shire rejected AbbVie’s latest £46.11 cash and share proposal arguing it is“fundamentally undervaluing” the company
Friday 20 June 2014
Shire has rejected a trio of possible offers worth up to £27.3 billion from a US suitor after vowing to remain independent.
The company, best-known for its Vyvanse blockbuster treatment for attention deficit hyperactivity disorder, faced the approaches from pharmaceuticals firm AbbVie while AstraZeneca was fending off a £63 billion takeover attempt from Pfizer.
Shire today said it rejected AbbVie’s latest £46.11 cash and share proposal, a 23 per cent premium to last night’s close, as “fundamentally undervaluing” the company.
But the shares leapt 14 per cent, or 522p, to 4260p as investors weighed into company, which has long been seen as a takeover target.
Chairman Susan Kilsby underlined the company’s growth prospects with a new target to double annual product sales, which account for the bulk of revenues, to $10 billion (£5.9 billion) by 2020, and urged shareholders to “take no action”.
She said: “The board believes the proposal fundamentally undervalued Shire and its prospects and that as an independent company Shire’s focused growth strategy will continue to deliver significant shareholder value and patient benefits.”
Shire stressed its 19 per cent rise in product sales growth over the past year, and the strong growth of its rare diseases unit, bolstered by the $4.2 billion deal for US company ViroPharma last year. Shire is building up the division as it faces more generic competitors to its ADHD drugs. “Shire has a long track record of delivering for shareholders and addressing unmet patient needs,” she added.
Panmure Gordon analyst Savvas Neophytou said Shire could be worth as much as £55 a share and noted the “distinct lack of the word ‘final’” anywhere in AbbVie’s announcement despite talks no longer taking place.
He added: “Shire’s rare diseases business is one of the hottest assets in biopharmaceuticals... Given the company’s growth characteristics, a premium valuation is warranted in our view.” The company also highlighted total shareholder returns of 99 per cent over the past year, including reinvested dividends.
Though London listed, Shire is domiciled for tax purposes in Ireland. If successful in the approach AbbVie planned to move its tax base to the UK under an inversion structure to cut its US tax bill, similar to Pfizer’s plans for Astra. Shire’s board also had “concerns regarding the execution risks associated with the proposed inversion structure”.
- 2 The West has it totally wrong on Lee Kuan Yew
- 3 #FreeTheNipple: Women in Iceland bare breasts in solidarity with trolled student
- 4 Scientists have discovered a simple way to cook rice that dramatically cuts the calories
Germanwings captain Patrick Sondenheimer tried to break into locked cockpit door 'with an axe' as plane was descending
Amanda Knox murder conviction: Italian court overturns verdict for US student and Raffaele Sollecito in the killing of Meredith Kercher
Saudi Arabia says it won't rule out building nuclear weapons
The battle for the Middle East's future begins in Yemen as Saudi Arabia jumps into the abyss
#FreeTheNipple: Women in Iceland bare breasts in solidarity with trolled student
Nigel Farage brands LGBT activists 'filth' and 'scum' and accuses them of scaring away his children after they invade his local pub
Ukip supporters are 55 or older, white and socially conservative, finds British Social Attitudes Report
JK Rowling responds to fan tweeting she 'can't see' Dumbledore being gay
Russia threatens Denmark with nuclear weapons if it tries to join Nato defence shield
Jeremy Clarkson sacked live: Alan Yentob 'wouldn't rule out' ex Top Gear host's BBC return
Germanwings plane crash live: Co-pilot Andreas Lubitz wanted to 'do something people would remember him for'
iJobs Money & Business
Negotiable: Recruitment Genius: To provide a prompt, friendly and efficient se...
Negotiable: Recruitment Genius: You will be the first point of contact for all...
£18000 - £24000 per annum + benefits: Ashdown Group: HR, Payroll & Benefits Of...
£35000 - £38000 per annum + benefits : Ashdown Group: A highly successful, int...